Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) announced on Tuesday the launch of Baclofen Oral Suspension, a generic alternative to Fleqsuvy.
Baclofen Oral Suspension is a treatment for spasticity from multiple sclerosis or spinal cord injuries and other spinal cord diseases. Fleqsuvy is marketed by Azurity Pharmaceuticals Inc.
Total US annual sales for Baclofen Oral Suspension amount to approximately USD39m, according to IQVIA data.
ANI Pharmaceuticals launches generic Baclofen Oral Suspension
Lutris Pharma names new director
Mikart adds Fette double-sided tablet presses
Biocon Biologics enters five-year partnership with Sandoz Australia
Rottendorf Pharma enhances operations with Rockwell Automation's FactoryTalk PharmaSuite MES
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US